Table 2 Clinical adverse events and biological abnormalities reported in our cohort of 96 patients.

From: Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients

 

Number of patients (%)

Clinical adverse events

Diarrhea

3 (3%)

Muscular pain

3 (3%)

Headache

4 (4%)

Fatigue

13 (13.5%)

Dizziness

1 (1%)

Insomnia

7 (7%)

Biological Abnormalities*

Total serum bilirubin

 Grade 1 (>ULN − 1.5 × ULN)

4 (4%)

 Grade 2 (>1.5–3.0 × ULN)

1 (1%)

CPK

 

 Grade 1 (>ULN − 2.5 × ULN)

4 (4%)

 Grade 2 (>2.5–5 × ULN)

1 (1%)

  1. *Grade classification according to “Common Terminology Criteria for Adverse Events v4.0”34 CPK: creatinine phosphokinase, ULN: upper limit of normal range.
Back to article page